Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference Life Science Investing
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 Life Science Investing
NRx Pharmaceuticals Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress Life Science Investing
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing Life Science Investing
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Life Science Investing
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research 2026 Annual Meeting Life Science Investing
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement Life Science Investing
TP-03 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus Life Science Investing
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease Life Science Investing
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services Life Science Investing